CALHM1 and its polymorphism P86L differentially control Ca\(^{2+}\) homeostasis, mitogen-activated protein kinase signaling, and cell vulnerability upon exposure to amyloid β

Ana José Moreno-Ortega,1,2,3 Izaskun Buendia,2,3 Lamia Mouhid,3 Javier Egea,1,2 Susana Lucea,2,3 Ana Ruiz-Nuño,1,2 Manuela G. López1,2,3 and María F. Cano-Abad1,2,3
1Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, Madrid, Spain
2Instituto Teófilo Hernando, Universidad Autónoma de Madrid, Madrid, Spain
3Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain

Summary

The mutated form of the Ca\(^{2+}\) channel CALHM1 (Ca\(^{2+}\) homeostasis modulator 1), P86L-CALHM1, has been correlated with early onset of Alzheimer’s disease (AD). P86L-CALHM1 increases production of amyloid beta (Aβ) upon extracellular Ca\(^{2+}\) removal and its subsequent adadbach. The aim of this study was to investigate the effect of the overexpression of CALHM1 and P86L-CALHM1, upon Aβ treatment, on the following: (i) the intracellular Ca\(^{2+}\) signal pathway; (ii) cell survival proteins ERK1/2 and Ca\(^{2+}\)/cAMP response element binding (CREB); and (iii) cell vulnerability after treatment with Aβ. Using aequorins to measure the effect of nuclear Ca\(^{2+}\) concentrations ([Ca\(^{2+}\)]\(_{n}\)) and cytosolic Ca\(^{2+}\) concentrations ([Ca\(^{2+}\)]\(_{c}\)) on Ca\(^{2+}\) entry conditions, we observed that baseline [Ca\(^{2+}\)]\(_{n}\) was higher in CALHM1 and P86L-CALHM1 cells than in control cells. Moreover, exposure to Aβ affected [Ca\(^{2+}\)]\(_{c}\) levels in HeLa cells overexpressing CALHM1 and P86L-CALHM1 compared with control cells. Treatment with Aβ elicited a significant decrease in the cell survival proteins p-ERK and p-CREB, an increase in the activity of caspases 3 and 7, and more frequent cell death by inducing early apoptosis in P86L-CALHM1-overexpressing cells than in CALHM1 or control cells. These results suggest that in the presence of Aβ, P86L-CALHM1 shifts the balance between neurodegeneration and neuronal survival toward the stimulation of pro-cytotoxic pathways, thus potentially contributing to its deleterious effects in AD.

Key words: Alzheimer’s disease; Ca\(^{2+}\) channel CALHM1; CREB; Ca\(^{2+}\) homeostasis; caspases; early apoptosis.

Introduction

Alzheimer’s disease (AD) is clinically characterized by progressive cognitive impairment that is believed to result from synaptic dysfunction and neurodegeneration initiated by the aggregated form of amyloid beta (Aβ) peptide (Hardy & Selkoe, 2002). Accumulated evidence suggests that AD is also linked to an imbalance of intracellular Ca\(^{2+}\) homeostasis (Bezprozvanny & Mattson, 2008; Green & LaFerla, 2008; Marambaud et al., 2009; Fernandez-Morales et al., 2012), because Ca\(^{2+}\) plays a critical role in maintaining cell survival; for example, a mild elevation of [Ca\(^{2+}\)]\(_{c}\) promotes neuronal survival and plasticity, whereas more pronounced elevations can cause neurotoxicity (Berridge et al., 1998; Cano-Abad et al., 2001). Thus, alterations in Ca\(^{2+}\) homeostatic mechanisms associated with aging, mutations in amyloid precursor protein (APP) and presenilins, and dysfunctional Ca\(^{2+}\) fluxes at the endoplasmic reticulum (ER) can promote neuronal cell death (Bezprozvanny & Mattson, 2008).

Although data from the literature indicate that neuronal death in AD is related to the action of Aβ on intracellular Ca\(^{2+}\) dyshomeostasis, little is known about the role of the novel Ca\(^{2+}\) channel, calcium homeostasis modulator 1 (CALHM1), in the disease. CALHM1 is expressed in all brain regions and neuronal cells, at the ER, and in the plasma membrane. CALHM1 generates Ca\(^{2+}\)-selective cation currents in the plasma membrane. It has also been shown to form a novel Ca\(^{2+}\)-permeable ion channel, whose gating is allosterically regulated by both membrane voltage and extracellular Ca\(^{2+}\) concentration; in addition, CALHM1 is insensitive to classic selective blockers of voltage-gated Ca\(^{2+}\) channels, although it is inhibited by nonselective and inorganic Ca\(^{2+}\) channel blockers such as Ca\(^{2+}\) (Dreses-Werringloer et al., 2008; Moreno-Ortega et al., 2010; Ma et al., 2012). But recently we described that CALHM1 is blocked by CGP37157 (Moreno-Ortega et al., 2015).

A polymorphism of CALHM1, P86L-CALHM1, which results in a proline to leucine substitution at codon 86, has been associated with early onset of sporadic AD (Dreses-Werringloer et al., 2008); however, this association remains controversial. Thus, while some studies have shown a significant correlation (Boada et al., 2010; Cui et al., 2010), others have failed to find such an association (Bertram et al., 2008). While it is accepted that P86L-CALHM1 is not a genetic risk factor for the development of AD, a meta-analysis has shown that this polymorphism modulates the age of disease onset (Lambert et al., 2010). Transient expression of the P86L-CALHM1 channel promotes accumulation of Aβ by altering membrane permeability to Ca\(^{2+}\) and, consequently, promotes an increase in [Ca\(^{2+}\)]\(_{c}\) (Dreses-Werringloer et al., 2008). However, evidence implicating a role for Aβ-induced disruption of Ca\(^{2+}\) homeostasis linked to CALHM1 or P86L-CALHM1 and the activation of cell death signaling pathways has not been reported.

Selective neuronal vulnerability is a feature of a number of neurodegenerative diseases, but the processes that target specific neurons for death while allowing others to remain healthy are unclear. The differential activation of an internal death program in vulnerable neurons has been proposed as a mechanism to explain the selective death of neurons (Schreiber & Baudry, 1995). However, it is equally likely that specific neuronal populations contain an intrinsic survival mechanism. The presence and/or activity of such a pathway in various cell types could partly explain their varying sensitivities to detrimental brain insults. Several studies have recently implicated the transcription factor c-AAMP response element-binding protein (CREB) as a possible regulator of a general survival program in neurons. CREB can be activated by various kinases in response to electrical activity, neurotransmitters, hormones,
and neurotrophins, thus promoting the expression of many genes that contain CAMP response elements (Finkbeiner et al., 1997; Hardingham & Bading, 1998). CREB also plays a central role in memory formation (West et al., 2001). The transcriptional activation of CREB is crucially dependent on phosphorylation of Ser133 by kinases such as Ca2+/calmodulin kinase (CaMK), ras/mitogen-activated protein kinase (MAPK), ERK1/2 (Wu et al., 2001), and protein kinases A and C (Hardingham et al., 1999). Extracellular signal-regulated kinases (ERKs) are key genes in activating survival pathways (Roskoski, 2012), and their transient activation plays an important role in memory-related processes (Costa & Silva, 2002).

As Ca2+ dyshomeostasis is found in AD and P86L-CALHM1 is considered a risk factor for AD, we investigated how native CALHM1 and P86L-CALHM1 could contribute to Ca2+ homeostasis, survival signaling pathways (namely, ERK and the transcription factor CREB), and cell survival at baseline or after treatment with Aβ. We used transfected HeLa cells with the empty vector (control) and cells transfected with vectors including CALHM1 and P86L-CALHM1 to study the kinetics of the changes of [Ca2+]c and [Ca2+]n, generated by reintroduction of Ca2+ and treatment with Aβ. We also analyzed ERK, CREB activation, and apoptosis pathways upon exposure to Aβ. Our results indicate that P86L-CALHM1 could contribute to neuronal vulnerability by affecting cytosolic and nuclear Ca2+ homeostatic mechanisms and survival signaling pathways.

Results

Effect of CALHM1 and P86L-CALHM1 overexpression on the nuclear concentration of Ca2+

Several authors have investigated the participation of CALHM1 expression in different Ca2+ compartments such as cytosol (Dreses-Werringloer et al., 2008; Moreno-Ortega et al., 2010; Ma et al., 2012), mitochondria ([Ca2+]m) (Moreno-Ortega et al., 2010), and ER ([Ca2+]ER) (Gallego-Sandin et al., 2011). However, the regulation of nuclear Ca2+ homeostasis by CALHM1 and P86L-CALHM1 has not yet been described.

Because CALHM1 is anchored to the ER membrane (Dreses-Werringloer et al., 2008) and the ER membrane constitutes the nuclear envelope, we hypothesized that upon CALHM1 opening, and the channel could be releasing Ca2+ from the ER into the nucleus. Furthermore, variations in the [Ca2+]n can promote changes in [Ca2+]c, that could regulate cellular functions ranging from proliferation to cell death (Alonso et al., 2011). Therefore, we used nuclear-targeted aequorin (nu_AEQ) to explore whether CALHM1 or P86L-CALHM1 overexpression could promote changes in [Ca2+]n upon reintroduction of Ca2+.

Cells transfected with nu_AEQ were initially perfused with a 0 Ca2+-EGTA solution for 2 min. This solution was then switched to another one containing 1 mM Ca2+. Figure 1A shows that the [Ca2+]n was stable at around 0.38 μM in control cells in 0 Ca2+/EGTA; in CALHM1 and P86L-CALHM1 cells, [Ca2+]n was quite stable at 1.83 and 1.5 μM, respectively. Upon reintroduction of 1 mM Ca2+, [Ca2+]n rose to a peak at 0.97 ± 0.09 μM and then decayed to near baseline values, indicating inactivation of the constitutive capacitative Ca2+ entry channel of the control HeLa cells. The kinetics of the transient [Ca2+]n in CALHM1-overexpressing cells were considerably different from those of the control; the activation rate was significantly slower and peaked at 2.79 ± 0.13 μM before slowly decaying to a stable plateau at around 1.5 μM. In P86L-CALHM1-overexpressing cells, the transient [Ca2+]n developed much more slowly, reaching a peak at 2.32 ± 0.16 μM and stabilizing as a plateau, with little decay.

Quantitative averaged data from 20, 34, and 29 experiments for control, CALHM1, and P86L-CALHM1 cells, respectively, show a 4.86-fold increase over baseline [Ca2+]n in CALHM1 cells and 3.98-fold increase for P86L-CALHM1 cells, with respect to the control cells.

Fig. 1 Kinetics of the nuclear Ca2+ transients ([Ca2+]n) measured using aequorin targeting the nucleus. (A) Typical traces of the time course of [Ca2+]n elevation elicited during the time period indicated. Ca2+ was reintroduced as indicated on the bottom horizontal bar. Data are represented as follows: (B) baseline [Ca2+]n, (C) time constant for activation (τon), (D) peak [Ca2+]n, transient amplitude, (E) time constant for inactivation (τoff), and (F) area under the curve (AUC) of the transients in cells overexpressing the empty vector (C), CALHM1, or P86L-CALHM1. Bar graphs of B–F were computed with pooled data from 20 experiments (control), 34 experiments (CALHM1), and 29 experiments (P86L-CALHM1) performed with cells from 10 different cultures and according to protocols such as those shown in A. Data are expressed as mean ± SEM. One-way ANOVA post hoc Bonferroni, *P < 0.05, **P < 0.01, ***P < 0.001.
(Fig. 1B). In addition, the kinetics of the \([\text{Ca}^{2+}]_{n}\) transients differed between the three cell types. For instance, the time constant for the rate of the transient rise \((\tau_{\text{on}})\) was 1.47-fold and 2.27-fold higher in CALHM1 and P86L-CALHM1 cells, respectively, than in control cells (Fig. 1C), suggesting slower activation of the \([\text{Ca}^{2+}]_{n}\) signal. Moreover, the peak heights were 2.86-fold and 2.34-fold greater (Fig. 1D). The rate of signal decay was considerably slower in CALHM1 cells \((\tau_{\text{off}}\;3.46\text{-fold higher})\) and in P86L-CALHM1 cells \((\tau_{\text{off}}\;3.41\text{-fold higher})\), with respect to control cells (Fig. 1E). Finally, we calculated the area under the curve (AUC) of each transient as a reflection of the total \([\text{Ca}^{2+}]_{n}\) considering the net rise in \([\text{Ca}^{2+}]_{n}\) from baseline for each cell type: we observed that it was 2.87-fold higher in CALHM1 and 3.03-fold higher in P86L-CALHM1 cells than in controls (Fig. 1F).

**CALHM1 and P86L-CALHM1 overexpression and \(\text{Ca}^{2+}\) release at nucleoplasma regions**

Activation of inositol 1,4,5-trisphosphate receptors (InsP\(_3\)R) is a key mechanism of \(\text{Ca}^{2+}\) entry into the nucleus. As the ER membrane forms part of the nuclear envelope and CALHM1 is anchored to the ER, we explored whether CALHM1 or P86L-CALHM1 overexpression could affect the kinetics of the \([\text{Ca}^{2+}]_{n}\) transients elicited by indirect InsP\(_3\)R activation by histamine. We first perfused cells with a \(\text{Ca}^{2+}\) solution of the transient rise \((0.67 \text{ M} \text{ histamine for} \;15 \text{ s})\). Figure 2A shows three superimposed typical traces on the \([\text{Ca}^{2+}]_{n}\) variations elicited by histamine-InsP\(_3\)R stimulation. Once more, baseline \([\text{Ca}^{2+}]_{n}\) was higher in CALHM1 and P86L-CALHM1 cells than in control (Fig. 2B). As far as the histamine-elicited transients were concerned, no significant changes were observed in the \(\tau_{\text{on}}\), peak \([\text{Ca}^{2+}]_{n}\), \(\tau_{\text{off}}\), or AUC between the three cell types (Figs. 2C–F). One interpretation of these results could be that slow inactivation of InsP\(_3\)R channels occurs upon \(\text{Ca}^{2+}\) leak through CALHM1 and P86L-CALHM1, which would in turn slower \(\text{Ca}^{2+}\) release into the nucleus owing to InsP\(_3\)R inactivation by \(\text{Ca}^{2+}\).

**Effects of \(\text{A} \beta\) on cytosolic \(\text{Ca}^{2+}\) signaling in cells overexpressing CALHM1 and P86L-CALHM1**

Previous results gave rise to the hypothesis that CALHM1 could behave as a leak channel regulating changes in the kinetics of nuclear \([\text{Ca}^{2+}]_{n}\) changes and, in so doing regulates \(\text{A} \beta\)/APP ratio levels in a \(\text{Ca}^{2+}\)-dependent manner (Dreses-Werringloer et al., 2008). However, the influence of extracellular \(\text{A} \beta\) on \(\text{Ca}^{2+}\) homeostasis in CALHM1- and P86L-CALHM1-overexpressing cells has not been investigated to date. To address this issue, we performed experiments to measure changes in \([\text{Ca}^{2+}]_{c}\); occurring during acute \(\text{A} \beta\) treatment. To reveal possible changes in the rate of \(\text{Ca}^{2+}\) entry through CALHM1 or P86L-CALHM1 channels, \([\text{Ca}^{2+}]_{c}\) was measured under the channel activating form, that is removal of extracellular \(\text{Ca}^{2+}\) \((0 \text{ \text{Ca}^{2+}/\text{EGTA}) and its subsequent addback (1 \text{ mM} \text{Ca}^{2+}) in the absence or presence of \(\text{A} \beta\).

In the absence of \(\text{A} \beta\), the addback of \(\text{Ca}^{2+}\) elicited a significant increase in the \([\text{Ca}^{2+}]_{c}\), reaching 4.34 and 1.25 \(\mu\text{M}\) in CALHM1 and P86L-CALHM1, respectively (Fig. 3A). In the presence of \(\text{A} \beta_{25-35}\) \((10 \text{ \mu}\text{M})\) and 1 \(\text{M}\) extracellular \(\text{Ca}^{2+}\), slight oscillations in baseline \([\text{Ca}^{2+}]_{c}\) in both CALHM1 and P86L-CALHM1 cells were detected (data not shown). Extracellular \(\text{Ca}^{2+}\) was then withdrawn and this protocol repeated in the presence of \(\text{A} \beta\); \(\text{Ca}^{2+}\) entry was significantly reduced in CALHM1- or P86L-CALHM1-overexpressing cells (Fig. 3B). Pooled data show that in CALHM1 cells, peak \([\text{Ca}^{2+}]_{c}\) was reduced by 40.32%, from 4.34 \(\mu\text{M}\) (no \(\text{A} \beta\)) to 1.75 \(\mu\text{M}\) (plus \(\text{A} \beta\)), whereas in P86L-CALHM1 cells, the peak was reduced by 44% from 1.25 to 0.55 \(\mu\text{M}\). In control cells, \([\text{Ca}^{2+}]_{c}\); changes were mild and similar in the presence or absence of \(\text{A} \beta\) (0.67 and 0.3 \(\mu\text{M}\), respectively) (Fig. 3C). These modifications seem to be specific for the toxic form of \(\text{A} \beta\) since the scramble sequence of \(\text{A} \beta_{25-35}\) did not afford significant modifications in the \([\text{Ca}^{2+}]_{c}\); (data not shown).

**Vulnerability of CALHM1- and P86L-CALHM1-overexpressing cells to different cytotoxic stimuli**

No significant baseline cell death was observed in HeLa cells transiently expressing the empty vector (control), CALHM1, or P86L-CALHM1 (Fig. 4A). When both types were incubated with oligomers of \(\text{A} \beta\)\(_{1-42}\), 5 \(\mu\text{M}\) for 24 h, only P86L-CALHM1-overexpressing cells showed significant cell toxicity (24% of cell death) compared with cells overexpressing the empty vector or the wild-type channel (Fig. 4B).

We also evaluated vulnerability to oxidative stress stimuli using phenylarsine oxide (PAO), which causes oxidative stress via a mitochondria-dependent mechanism (Vay et al., 2009). PAO reduced cell viability in all three cell types (Fig. 4C). Therefore, cells expressing P86L-CALHM1...
did not show higher vulnerability to oxidative stress, in contrast to the observations with Aβ treatment.

Activation of apoptosis in CALHM1- and P86L-CALHM1-overexpressing cells upon Aβ exposure

To clarify the mechanism involved in the cell death observed in Fig 4B, the next reasonable step was to explore whether treatment with Aβ induced apoptosis in cells overexpressing CALHM1 or P86L-CALHM1. To this end, we explored the different apoptosis stages in control, CALHM1, and P86L-CALHM1 cells upon exposure to Aβ1-42 (5 μM) for 24 h. We observed a clear tendency toward early triggering of apoptosis only in cells overexpressing the mutated form P86L-CALHM1 at 3 and 6 h (data not shown). Thus, we incubated the cells overexpressing CALHM1 and P86L-CALHM1 for a longer time period to determine how long it would take the apoptosis stage upon treatment with Aβ. After 24 h, only P86L-CALHM1-overexpressing cells activated the early apoptosis pathway (Fig. 5B). These results were independent of cell type, because the neuronal hippocampal cell line HT-22 overexpressing CALHM1 and P86L-CALHM1 were also vulnerable when treated with Aβ25-25 (50 μM) for 24 h. (Supplemental Results and figures).

Regulation of ERK and CREB in CALHM1- and P86L-CALHM1-overexpressing cells

Ca²⁺ is critically involved in synaptic activity and memory formation by regulating specific signal transduction pathways that implicate key protein effectors, such as CAMK, MAPK/ERK, and CREB. Therefore, we performed experiments to clarify whether Aβ-treated cells expressing CALHM1 or P86L-CALHM1 could be regulating a key gene implicated in survival pathways such as ERK and CREB. No significant changes were detected in the expression of p-ERK or t-ERK between controls and CALHM1 cells that were untreated or treated with Aβ (5 μM of oligomers of Aβ1-42 for 1 h). However, treatment with Aβ significantly decreased both p-ERK expression and t-ERK expression in P86L-CALHM1 cells (Fig. 6A and C).

We also measured CREB, a transcriptional factor involved in memory and neuronal survival that can be activated via its phosphorylation at serine (Ser) 133 by several kinases, including ERK. In P86L-CALHM1 cells treated with Aβ, we observed significantly lower expression of p-CREB...
than P86L-CALHM1 cells not treated with Aβ (Fig. 6B). As for t-CREB, P86L-CALHM1 cells treated with Aβ showed significantly lower expression levels than control cells exposed to Aβ; a trend toward lower expression levels was also observed in CALHM1-expressing cells, although it was not statistically significant (Fig. 6D).

Discussion

We found alterations in [Ca²⁺]n signaling in HeLa cells transfected with the wild-type CALHM1 Ca²⁺ channel and its mutated form P86L-CALHM1. Baseline [Ca²⁺]n values in CALHM1 and P86L-CALHM1 cells were twice those of controls both after perfusion with a 0 Ca²⁺/EGTA solution and under physiological conditions in 1 mM Ca²⁺ (Figs. 1B and 2B). Furthermore, upon reintroduction of Ca²⁺, the kinetics of the [Ca²⁺]n transients generated developed at a slower rate and decayed to a long-lasting plateau in CALHM1 and P86L-CALHM1 compared with control cells (Figs. 1A, C, E). Of interest was the fact that peak and total [Ca²⁺]n elevations (AUC) were somewhat higher in the cells expressing both forms of CALHM1; the differences detected are similar to those observed with [Ca²⁺]c under the same experimental conditions (Moreno-Ortega et al., 2010), indicating that [Ca²⁺]n depends at least partially on [Ca²⁺]cit (Alonso & Garcia-Sancho, 2011). Except for a slower decay in P86L-CALHM1 cells, the transients were similar to those of CALHM1 cells. Slower and longer [Ca²⁺]n signals in CALHM1 and P86L-CALHM1 can be altered because, upon transfection, these channels are preferentially expressed in ER membranes (Dreses-Werringloer et al., 2008) and these membranes form the nuclear envelope; thus, the CALHM1 channel could be eliciting elevation of [Ca²⁺]n by simply acting as a leak channel or as an InsP₃R pore. This last possibility seems unlikely.
because the \([\text{Ca}^{2+}]_n\), transients generated by histamine were similar in control cells and in CALHM1 and P86L-CALHM1 cells (Fig. 2). It therefore seems plausible that CALHM1 behaves as a leak \(\text{Ca}^{2+}\) channel and that the greater baseline \([\text{Ca}^{2+}]_c\), in CALHM1 and P86L-CALHM1 cells could be explained by \(\text{Ca}^{2+}\) leakage from the ER lumen into the nucleus. This interpretation is in line with the idea that the nucleus might have specific \(\text{Ca}^{2+}\) transients at specific functionally distinct subcompartments; in fact, the nuclear reticulum can generate localized nuclear \(\text{Ca}^{2+}\) gradients (Gerasimenko et al., 1995). The alternative hypothesis implies that cytosolic \(\text{Ca}^{2+}\) signals can generate nuclear \(\text{Ca}^{2+}\) signals by simple \(\text{Ca}^{2+}\) diffusion (Gerasimenko et al., 1995; Chamero et al., 2008; Alonso & Garcia-Sancho, 2011).

Given that the mutated channel P86L-CALHM1 causes accumulation of Aβ and thus increases Aβ levels in a \(\text{Ca}^{2+}\)-dependent manner (Dreses-Werringloer et al., 2008), it could be responsible for cell vulnerability. In fact, we observed that expression of P86L-CALHM1 significantly decreased cell viability (Fig. 4B) by initiating early apoptosis (Fig. 5B) in cells exposed to Aβ compared with treated cells overexpressing the empty vector or the CALHM1 channel. When control, CALHM1-, or P86L-CALHM1-overexpressing cells were exposed to channel activation by \(\text{Ca}^{2+}\) addback, no significant vulnerability was observed in any of the cells; these results are in agreement with those reported by Dreses-Werringloer and co-workers (Dreses-Werringloer et al., 2008). However, mitochondrial oxidative stressor, such as PAO, did not significantly increase the vulnerability of P86L-CALHM1-expressing cells compared with control or CALHM1-expressing cells (Figs. 4C), indicating the presence of a different cell death mechanism between mitochondrial stressors and P86L-CALHM1-induced vulnerability. Additionally, the molecular mechanism of cell death implicated in P86L-CALHM1 cells exposed to Aβ seems to be related to activation of early apoptosis (Fig. 5B); during this phase, phosphatidylserine is flipped to the outer side of the plasma membrane in a caspase-dependent process (Bouchier-Hayes et al., 2008); therefore, activation of caspases 3 and 7 was observed (see Fig. 5C). It is noteworthy that the cell death mechanism triggered by P86L-CALHM1 in the presence of Aβ does not depend on the cell type, because the neuronal hippocampal cell line HT-22 is also vulnerable to this stimulus, which triggers early apoptosis (Fig. S2). Moreover, other AD-like insults such as okadaic acid (OKA) induced cell death in Hela P86L-CALHM1-overexpressing cells versus control and CALHM1, significantly (Fig S3). Taken together, these results could add evidence of the influence of P86L-CALHM1 on the onset of AD and Aβ.

The enhanced vulnerability of P86L-CALHM1-overexpressing cells upon exposure to Aβ has been associated with the reduction observed in the expression of proteins related to cell survival signaling pathways such as ERK and CREB (Walton & Dragunow, 2000; Lonze & Ginty, 2002). In fact, in the presence of Aβ, P86L-CALHM1-expressing cells showed lower expression levels of p-ERK and t-ERK than controls (Fig. 6A, C). Changes in phosphorylation of ERK in CALHM1 and P86L-CALHM1 were also recently described by Dreses-Werringloer et al. (2013).

The transcriptional factor CREB has been related to neuronal survival, synaptic plasticity, and memory (Walton & Dragunow, 2000); phosphorylation of its Ser133 has been identified as the key event that must occur for CREB to function as a stimulus-dependent transcriptional activator. After phosphorylation at Ser133, CREB recruits CREB-binding protein to act as a transcriptional coactivator (Chrivita et al., 1999). A number of \(\text{Ca}^{2+}\)-dependent signaling pathways, such as MAPK/ERKs, have been implicated in the nuclear phosphorylation of CREB at Ser133. Reduction in t-ERK and p-ERK in cells expressing the mutated form of the channel could account for the reduction in p-CREB detected in these cells (Fig. 6B). Curiously, cells overexpressing CALHM1 tended to reduce t-CREB values, although this was not related to a diminution in the active form, p-CREB, or the lack of alterations found in p-ERK. Therefore, cell vulnerability was not increased.

Conclusion

We showed that P86L-CALHM1 impairs plasma and nuclear membrane \(\text{Ca}^{2+}\) permeability, increases cytosolic and nuclear steady-state \(\text{Ca}^{2+}\) levels, depresses the cell survival ERK/CREB pathway, and increases cell vulnerability to Aβ by triggering early apoptosis and activation of caspases 3 and 7. Therefore, in the presence of Aβ, P86L-CALHM1 seems to shift the balance between neurodegeneration and neuronal survival toward the stimulation of pro-cytotoxic pathways, which may in turn contribute to its deleterious effects in AD.

Experimental procedures

Chemicals

Metafectene® was purchased from Biontex (München, Germany). Wild-type coelenterazine was purchased from Biotium (Hayward, CA, USA). 4′6-diamidino-2-phenylindole (DAPI), Aβ(25–35), anti-β-actin, histamine, human Aβ(1–42), paraformaldehyde, propidium iodide (PI), thiazoyl blue tetrazolium bromide (MTT), TritonX-100, and Tween 20 were purchased from Sigma (Madrid, Spain). The antibodies anti-c-Myc and anti-CALHM1 and the PVDF membranes were from Millipore (Madrid, Spain), and Alexa 488 and Image i-T-FX signal enhancer were from Thermo Fisher Scientific (Madrid, Spain). The BCA Protein Assay Kit Reagent was from GE Healthcare, and the ECL Advance™ Western Blotting Detection Kit was from Fisher Scientific. The DAKO® mounting medium was purchased from DAKO (Barcelona, Spain). The antibodies anti-CREB, anti-p-CREB, and anti-p-ERK were from Cell Signalling (Madrid, Spain); anti-total ERK and secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, USA). We analyzed apoptosis using the FITC Apoptosis Detection Kit (Immunostep, Salamanca, Spain). Other general chemicals were purchased from Sigma (Madrid, Spain) or Panreac Química S.L.U. (Barcelona, Spain). The cDNA encoding for aequorins was a gift from Professor Tulio Pozzan (University of Padua). The cDNA encoding for CALHM1 and P86L-CALHM1 was a gift from Professor Philippe Marambaud (Albert Einstein College of Medicine, New York, USA).

Culture of HeLa cells

HeLa cells were grown in plastic flasks in DMEM supplemented with 10% fetal bovine serum, 2 mM glutamine, 25 U mL⁻¹ penicillin, and 25 μg mL⁻¹ streptomycin (all products purchased from Lonza, Basel, Switzerland).

Measurements of \([\text{Ca}^{2+}]_n\) and \([\text{Ca}^{2+}]_c\) with aequorins

Cell experiments were performed with 8 × 10⁴ cells seeded on 12-mm diameter coverslips and grown to 60–70% confluence. Transfection with the genetically encoded photoprotein aequorins targeting the nucleus (nu_AEQ) or cytosol (cyt_AEQ) was achieved using Metafectene® as described elsewhere for cells (Moreno-Ortega et al., 2010). Empty vector (control), or vectors containing CALHM1 or P86L-CALHM1 were transiently co-transfected with aequorins at a ratio of 1:1. Experiments to measure changes in \([\text{Ca}^{2+}]_n\) or \([\text{Ca}^{2+}]_c\) were performed 36 to 48 h after transfection. The two recombinant proteins were
HeLa cells expressing nu_AEQ or cyt_AEQ were reconstituted by adding 5 μM wild-type coelenterazine for 1.5 h before the experiment. To ensure the total translocation of nu_AEQ to the nucleus, cells were incubated with dexamethasone 10 μM for 2 h immediately before the experiment was carried out (Brini et al., 1995). The cell monolayer was continuously superfused at room temperature (24 ± 2 °C) with Krebs–Hepes buffer (KHB) of the following composition: 125 mM NaCl, 5 mM KCl, 1 mM NaH2PO4, 1 mM MgSO4, 5.5 mM glucose, and 20 mM HEPES (pH 7.4); the zero Ca2+ solution contained 0.5 mM ethylene glycol tetraacetic acid. To induce entry of Ca2+, KHB deprived of Ca2+ was switched to another solution containing 1 mM CaCl2, as specified in the figure legends. When used, 10 μM Aβ1–42 or 100 μM histamine was added to the KHB. Light emission was measured in a purpose-built luminometer and calibrated in terms of [Ca2+]l, as described by (Rizzuto et al., 1992). At the end of the experiment, cells were lysed by superfusing them with KHB containing 10 μM CaCl2 and 100 μM digitonin to expose them to excess Ca2+ to burn out the aequorin remaining at the end of each experiment and to normalize the Ca2+ transients to the fraction of total aequorin consumed at each point during the experiment.

Cell treatment with a mixture of protofibrils and oligomers of Aβ1–42
HeLa cells were seeded on 24-well plates and transfected as described above; 24 h after transfection, cells were treated with a mixture of protofibrils and oligomers of Aβ1–42 (5 μM) for 1 h and then harvested and lysed to determine the expression of CREB, pSer133CREB, ERK1/2, and pERK1/2 (Western blot).

Aggregation of Aβ1–42 at 5 μM was achieved as previously described (Parodi et al., 2010). Briefly, human Aβ1–42 was dissolved with dimethylsulfoxide (DMSO) at 2.3 mM; an aliquot of the 2.3-mM solution was then dissolved in PBS to a final concentration of 50 μM. Finally, this solution was incubated at 37 °C for 2 h under constant shaking.

Monitoring of cell viability
Cell viability was measured using an MTT assay as described elsewhere (Alonso et al., 2013). Briefly, 5 × 104 HeLa cells were seeded in 48-well plates and transfected with 0.5 μM of empty vector, CALHM1, or P86L-CALHM1. Twenty-four hours after transfection, cells were treated with 5 μM of aggregated Aβ1–42, oligomycin (10 μM) plus rotenone (30 μM), or phenylarsine oxide (PAO, 1 μM) for 24 h. Cells were then incubated with MTT reagent for reducing for 30 min to form formazan crystal, which was then dissolved with DMSO. Optical density (OD) was read using an ELISA reader at 540 nm (Berthold Detection Systems, Sintia). Cell viability was expressed as a percentage of the control and calculated using the following equation: viability = [OD test/OD baseline] × 100.

Analysis of apoptosis phases
We analyzed the different phases of apoptosis using the FITC Apoptosis Detection Kit (Immunostep, Salamanca, Spain), which is based on the ability of annexin V to bind specifically to phosphatidylserine flipped into the outer layer of the plasma membrane and the ability of the nonvital dye propidium iodide (PI) to bind to DNA only in altered membrane cells. Thus, double staining enables discrimination between intact cells (annexin V-negative and PI-negative), early apoptotic cells (annexin V-positive, PI-negative), and late apoptotic cells (annexin V-positive and PI-positive) or necrotic cells (without the characteristic cell integrity).

In brief, HeLa (2 × 105) cells were seeded in 6-well plates and transfected with 0.75 μg of empty vector and 2 μg of CALHM1 or P86L-CALHM1. Twenty-four hours after transfection, HeLa cells were treated for 24 h with 5 μM of a mixture of protofibrils and oligomers of Aβ1–42 and collected and incubated with fluorescent annexin V and PI. Apoptosis was determined by flow cytometry.

Measurement of caspase activation
We measured the activation of caspases 3 and 7 using a commercial kit based on luminescence (Caspase-Glo (R) 3/7 Assay, Promega Biotech Ibérica S.L., Madrid, Spain) as described by (Alonso et al., 2013). In brief, 105 HeLa cells were seeded in 48-well plates and transfected with 0.5 μg of empty vector, CALHM1, or P86L-CALHM1. Twenty-four hours after transfection, cells were treated with 5 μM of a mixture of protofibrils and oligomers of Aβ1–42 for 8 h. The readings were performed in black 96-well plates with a plate reader (Glo-Max Multi Detection System, Promega Biotech Ibérica S.L., Madrid, Spain). Activation of caspases 3 and 7 is expressed as a percentage of nontreated transfected cells.

Measurement of protein expression by Western blot
HeLa cells transfected with 0.5 μg of empty vector, CALHM1, or P86L-CALHM1 and treated or not with 5 μM of a mixture of protofibrils and oligomers of Aβ1–42 for 24 h were lysed with 100 μL of cold lysis buffer containing 1% Nonidet P-40, 10% glycerol, 137 mM NaCl, 20 mM Tris-HCl pH 7.5, 1 mg mL−1 leupeptin, 1 mM phenylmethylsulfonyl fluoride, 20 mM NaF, 1 mM Na3P2O7, and 1 μM Na3PO4. Once the amount of protein was quantified using the BCA Protein Assay Kit reagent, electrophoresis was performed by running 30 μg of protein in polyacrylamide gels for 2 h at constant amperage. Proteins were transferred to PVDF membranes for 2 h at 70 mA. Membranes were then blocked for 2 h with Tween 20-Tris Buffered Saline (TTBS) containing albumin 4% and incubated with anti-p-CREB, anti-total CREB and anti-ERK, anti-P-CREB, or anti-total CREB and anti-β actin for 2 h. After washing several times with TTBS, the corresponding secondary antibodies were added for 45 min. Finally, the membranes were revealed using the Western Blotting Detection Kit (Thermo Fisher Science) and analyzed and quantified using Scion-Image software (Scion Corporation Informer Technologies Inc., Meyer Instruments Inc., Houston, EEUU).

Statistics
Values are given as mean ± SEM. The statistical differences between means were assessed using the t-test or ANOVA and Bonferroni’s, Dunnett’s, or Tukey’s tests in a post hoc analysis. Differences between experimental groups were considered statistically significant at P < 0.05.

Acknowledgments
We are grateful to Dr. Philippe Marambaud (Albert Einstein College of Medicine, New York, USA) for the gifts of cDNAs for CALHM1 and P86L-CALHM1. We thank Professor Tullio Pozzan (University of Padua, Italy) for cDNAs for cyt_AEQ and nu_AEQ. We thank Ms Francisca Molina for her excellent work in the confocal experiments and Laura Molero, PhD, for her help in the flow cytometry measurements.
Funding

This work was partly supported by the following grants: Ministerio de Economía y Competitividad, FPU Program, Refs. AP2009/0343 (AJMO) and AP2010/1219 (IB). ARN: FIS PI10/01426. MGL: Ministerio de Economía y Competitividad, Ref. SAF2012-23332. MCCA: Consolidación de grupos de investigación UAM-CAM 1004040047. We also thank Fundación Teofilo Hernando, Madrid, Spain, for their continued support.

Conflict of interest

None declared.

References

Alonso E, Cano-Abad MF, Villarroya M, Garcia AG, Gabilan NH, Lopez MG (2010) Mitochondria Ca(2+)-release channel CALHM1 reduces the calcium content of the endoplasmic reticulum and is required for cell survival. *J. Biol. Chem.* 285, 19440–19451.

Boukris C, Caron A, Gagnier M, Parent A, Hogue B, Montpetit P, Fratini A, Schneck A, Carrier S, Kurek P, Goudreau S, Pouliot S, Robert D, Veltchev L, Weigand M, St-Pierre J (2013) The Ca(2)+ channel-like modulator CALHM1 controls Ca(2+) homeostasis in human and murine podocytes. *Proc. Natl Acad. Sci. USA* 110, 19686–19710.

Flinkbein S, Tavaoio SF, Maloratsky A, Jacobs KM, Harris KM, Greenberg ME (1997) CREB: a major mediator of neuronal neurotrophin responses. *Neuron* 19, 1031–1047.

Gallego-Sandin S, Alonso MT, Garcia-Sancho J (2011) Calcium homeostasis modulator 1 (CALHM1) reduces the calcium content of the endoplasmic reticulum (ER) and triggers ER stress. *Biochem. J.* 437, 469–475.

Gerasimenko OV, Gerasimenko JV, Tepikin AV, Petersen OH (1995) ATP-dependent accumulation and inositol trisphosphate- or cyclic ADP-ribose-mediated release of Ca(2+) from the nuclear envelope. *Cell* 80, 429–444.

Green KN, Laferla FM (2008) Linking calcium to Alzheimers disease. *Neuron* 59, 190–194.

Hardingham GE, Bading H (1998) Nuclear calcium: a key regulator of gene expression. *BioMetals* 11, 345–358.

Hardingham GE, Chavila S, Cruzalegui FH, Bading H (1999) Control of recruitment and transcription-activating function of CBP determines gene regulation by NMDA receptors and L-type calcium channels. *Neuron* 22, 789–798.

Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 297, 353–356.

Lambert JC, Sleighers K, Gonzalez-Perez A, Ingelsson M, Beecham GW, Hiltunen M, Combarros O, Bullido MJ, Brouwers N, Bettens K, Barr C, Pasquier F, Richard F, Dekosky ST, Haines JL, Tzogoni G, Fivert N, Dargues JP, Tzoucreo C, Engelborghs S, Arbosio B, Coto E, De Deyn P, Del Zompo M, Mateo I, Boada M, Antunez C, Lopez-Arrieta J, Epelbaum J, Schieide BM, Frank-Garcia A, Giedraitis V, Helisalmi S, Porcellini E, Pilotto A, Forti P, Ferri R, Delpeine M, Zelenika D, Lathrop M, Scarpini E, Mann D, Lendon C, Campion D, Amouyel P, Davies P, Foskett JK, Hardingham GE, Chawla S, Cruzalegui FH, Bading H (1999) Control of recruitment and transcription-activating function of CBP determines gene regulation by NMDA receptors and L-type calcium channels. *Neuron* 22, 247–255.

Lonze BE, Ginty DD (2002) Function and regulation of CREB family transcription factors in the nervous system. *Neuron* 35, 605–623.

Ma Z, Siebert AP, Cheung KH, Lee RJ, Johnson B, Cohen AS, Vingtedoux V, Mambraud P, Foskett JK (2012) Calcium homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca(2+) regulation of neuronal excitability. *Proc. Natl Acad. Sci. USA* 109, E1963–E1971.

Mamedo-Paredes P, Deves-Wieringloer U, Vingtedoux V (2009) Calcium signaling in neurodegeneration. *Mol. Neurodegener.* 4, 20.

Moreno-Ortega A, Ruiz-Nuno A, Garcia AG, Cano-Abad MF (2010) Mitochondria sense with different kinetics the calcium entering into HeLa cells through calcium channels CALHM1 and mutated P86L-CALHM1. *Biochem. Biophys. Res. Commun.* 391, 722–726.

Moreno-Ortega A, Martinez-Sanz FJ, Lujan-Cuesta R, De Los RC, Cano-Abad MF (2015) Benzothiazepine CGP37157 and its 2′-isopropyl analogue modulate Ca(2+) entry through CALHM1. *Neuroparmacology* 95, 503–510.

Parodi J, Sepulveda FJ, Roa J, Opazo C, Inestrosa NC, Aguayo LG (2010) Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. *J. Biol. Chem.* 285, 2506–2514.

Rizzuto R, Simpson AW, Brin M, Pozzan T (1992) Rapid changes of mitochondrial Ca(2+) revealed by specifically targeted recombinant aquaporin. *Nature* 358, 325–327.

Roskoski R Jr (2012) ERK1/2 MAP kinases: structure, function, and regulation. *Pharmacol. Res.* 66, 105–143.

Schreier SS, Baudry M (1995) Selective neuronal vulnerability in the hippocampus—a role for gene expression? *Trends Neurosci.* 18, 446–451.

Vay L, Hernandez-Samigel E, Lobaton CD, Moreno A, Montero M, Alvarez J (2009) Mitochondrial free [Ca(2+)](E) levels and the permeability transition. *Cell Calcium* 45, 243–250.

Walton MR, Dragunow I (2000) Is CREB a key to neuronal survival? *J. Cell Sci.* 113, 1149–1161.
Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.

Fig. S1 Cellular localization of CALHM1 and P86L-CALHM1.

Fig. S2 Cell vulnerability after treatment with Aβ25–35 in HT-22.

Fig. S3 Early apoptosis triggered by treatment with Aβ25–35 in CALHM1- and P86L-CALHM1-expressing HT-22 cells.

Fig. S4 Dose response curve of Okadaic Acid.

Data S1 Supplemental Material and Methods.